Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Genomics Research Highlighted at Lupus Conference

Larry Beresford  |  Issue: June 2019  |  June 17, 2019

Natali_ Mis / shutterstock.com

Natali_ Mis / shutterstock.com

SAN FRANCISCO—The challenges of trying to solve the puzzle of lupus, in light of its broad heterogeneity of symptoms, manifestations in clinical involvement and treatment response, and the sheer complexities of the immune system, are driving researchers into ever more elaborate investigations of how the immune system functions in lupus patients.

Genetic, transcriptomic and epigenetic research strategies were presented in a plenary session at the 13th International Congress on Systemic Lupus Erythema­tosus (SLE), held April 5–8. Researchers detailed their attempts to explore gene expression data, different pathways of genetic immunoregulation, novel regulatory elements at the cellular and molecular levels and data mining.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For a condition that might not even be a single disease, and for which the causes may involve interactions of genetic, epigenetic and environmental factors, this kind of cutting-edge genetic research points toward a variety of future treatment strategies and responses.

Cristina Lanata, MD, assistant adjunct professor of rheumatology at the University of California, San Francisco, chaired the plenary session on genetics and epigenetics at the conference and noted every presenter had a different story to tell about the genetic and epigenetic drivers of lupus. Epigenetics involves modifications in the expression of genes rather than in their underlying genetic code. These biologic mechanisms switch genes on or off, and the epigenome has been implicated in a variety of immune-mediated rheumatologic conditions.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“What we saw at the plenary was a variety of research strategies that are integrating previous knowledge regarding genetic risk factors for SLE and taking them forward with functional studies. These ranged from very controlled molecular studies to new mouse models of SLE. We also saw population-based approaches that try to integrate different layers of –omics data to stratify SLE into different subtypes according to their molecular characteristics, with the hope of better targeting SLE patients with the appropriate therapies.” Dr. Lanata said.

Gene Expression Data

Presenter Marta E. Alarcón-Riquelme, MD, PhD, head of medical genomics at the University of Granada, Spain, described her group’s efforts to use gene expression data from a database of 80 pediatric and 65 adult patients with lupus and six other systemic autoimmune diseases using multi-omic integrative analysis.1 “We took all the gene expression data there were,” she said.

“There is controversy in the field over whether lupus is actually one disease,” Dr. Alarcón-Riquelme noted. “Does its heterogeneity point to different mechanisms of disease? What lies behind the response or non-response to treatment? Can we subtype autoimmune disease in a more biological way, regardless of clinical manifestations of disease? Can we differentiate subgroups based on their genetic markers?” Ultimately, she asked, can research advance from a clinical diagnosis of lupus and other rheumatologic conditions to a molecular diagnosis, and would that facilitate drug repurposing and more individually targeted therapies?

Timothy Niewold, MD, director of NYU Langone’s Judith & Stewart Colton Center for Autoimmunity, also discussed sub-phenotype mapping to better understand lupus genetics, and, in particular, genetic associations with higher levels of serum interferon alpha circulating in the blood of lupus patients.2

His group looked at 1,400 SLE patients to map the genes impacting type 1 interferon. They found two single nucleotide polymorphisms specifically associated with higher interferon alpha levels in the blood of European Americans. This research aims to understand what these variant genes do and how that impacts high interferon levels, Dr. Niewold told participants. “We feel there is a relationship between type 1 interferon and lupus pathogenesis. But there are probably multiple roads to lupus, and not all involve higher levels of interferon.”

Nan Shen, MD, PhD, professor of medicine and director of the Shanghai Institute of Rheumatology at Renji Hospital, Shanghai Jiao Tong University School of Medicine, China, studies regulatory RNA as part of epigenetic study, and has discovered a micro-RNA that is an element regulating gene expression.3 Future longitudinal studies can use the stratification that was discovered and apply it to identifying the mechanisms of non-response to treatment.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:epigeneticsgenomic researchgenomicsInternational Congress of Lupus

Related Articles

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    July 18, 2019

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Genome-Wide Association Studies of SLE

    February 12, 2011

    What do these studies tell us about disease mechanisms in lupus?

    Research Advances Continue in the Fight Against Lupus

    June 17, 2019

    SAN FRANCISCO—The 13th International Congress on Systemic Lupus Erythematosus (SLE), held April 5–8, highlighted continuing advances in the fight against lupus, a chronic, inflammatory, autoimmune disease affecting multiple organ systems. The rheumatologist’s ability to control this incurable and life-threatening condition is limited both by its heterogeneous presentation and by the lack of successful treatment options,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences